american diabetes association pancreatitis history glp-1 receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy american diabetes association pancreatitis history

These metabolic improvements not only support effective weight loss but also reduce long-term risks associated with diabetes, heart disease, and obesity-related complications

doi:10.1001/jamanetworkopen.2025.21016 2

As a medical weight loss clinician and a medical weight loss training company owner its good to see that research is helping us understand the mechanisms of action of these drugs further

Optometrists should perform a baseline dilated comprehensive eye examination on patients who take these medications for any reason to determine their pre-existing level of DR and whether they have any risk factors for developing NAION

The product half-life is 2.4 hours, which allows for twice-daily administration, and is a large improvement over endogenous GLP-1 [19]

This information could be valuable in the decision to proceed with RSI (93.5%) vs cancelling the case (3.5%)